• Brad Ringeisen, chemist and executive director of the Innovative Genomics Institute, is working on two approaches to deliver CRISPR-Cas9 treatment to target cancer cells.
• The first approach is to use antibodies to bind to something that’s only found on a specific cell type.
• The second approach is to use envelope delivery vehicles, which take certain parts of a virus’ targeting system to help specifically target a certain cell type or tissue type.
• Intellia Therapeutics has already shown that CRISPR-Cas9 treatment can be applied intravenously to treat a liver disease.
• The dream is to do an infusion and then monitor the patient for a day or two, as this would be the most efficient and successful way to treat cancer with CRISPR-Cas9.
Published February 14, 2023
Visit Nautilus to read Brian Gallagher’s original post Will CRISPR Cure Cancer?